HomeCompareTDRK vs ABBV

TDRK vs ABBV: Dividend Comparison 2026

TDRK yields 28571.43% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 TDRK wins by $1.8174438113797412e+21M in total portfolio value
10 years
TDRK
TDRK
● Live price
28571.43%
Share price
$0.01
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1.8174438113797412e+21M
Annual income
$1,805,016,220,998,010,500,000,000,000.00
Full TDRK calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — TDRK vs ABBV

📍 TDRK pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodTDRKABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, TDRK + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
TDRK pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

TDRK
Annual income on $10K today (after 15% tax)
$2,428,571.43/yr
After 10yr DRIP, annual income (after tax)
$1,534,263,787,848,309,000,000,000,000.00/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, TDRK beats the other by $1,534,263,787,848,309,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of TDRK + ABBV for your $10,000?

TDRK: 50%ABBV: 50%
100% ABBV50/50100% TDRK
Portfolio after 10yr
$908721905689870598144.00M
Annual income
$902,508,110,499,005,300,000,000,000.00/yr
Blended yield
99.32%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

TDRK
No analyst data
Altman Z
-3.5
Piotroski
1/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

TDRK buys
0
ABBV buys
0
No recent congressional trades found for TDRK or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricTDRKABBV
Forward yield28571.43%3.06%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$1.8174438113797412e+21M$102.3K
Annual income after 10y$1,805,016,220,998,010,500,000,000,000.00$24,771.77
Total dividends collected$1.816625906206534e+21M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: TDRK vs ABBV ($10,000, DRIP)

YearTDRK PortfolioTDRK Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$2,867,843$2,857,142.86$11,550$430.00+$2.86MTDRK
2$768,847,726$765,779,134.08$13,472$627.96+$768.83MTDRK
3$192,691,632,776$191,868,965,708.97$15,906$926.08+$192691.62MTDRK
4$45,147,257,398,343$44,941,077,351,272.53$19,071$1,382.55+$45147257.38MTDRK
5$9,889,057,995,779,864$9,840,750,430,363,638.00$23,302$2,095.81+$9889057995.76MTDRK
6$2,025,084,628,942,200,600$2,014,503,336,886,716,000.00$29,150$3,237.93+$2025084628942.17MTDRK
7$387,709,524,857,534,600,000$385,542,684,304,566,450,000.00$37,536$5,121.41+$387709524857534.56MTDRK
8$69,399,422,486,233,860,000,000$68,984,573,294,636,305,000,000.00$50,079$8,338.38+$69399422486233856.00MTDRK
9$11,614,570,450,215,628,000,000,000$11,540,313,068,155,356,000,000,000.00$69,753$14,065.80+$11614570450215628800.00MTDRK
10$1,817,443,811,379,741,200,000,000,000$1,805,016,220,998,010,500,000,000,000.00$102,337$24,771.77+$1.8174438113797412e+21MTDRK

TDRK vs ABBV: Complete Analysis 2026

TDRKStock

Tiderock Companies Inc. operates as a real estate investment, advisory, and development company. It develops apartments, office spaces, hotels, student housing, assisted living, and higher education academic facilities. The company was formerly known as iPure Labs, Inc. and changed its name to Tiderock Companies Inc. in September 2021. Tiderock Companies Inc. was incorporated in 2000 and is based in Henderson, Nevada.

Full TDRK Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this TDRK vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

TDRK vs SCHDTDRK vs JEPITDRK vs OTDRK vs KOTDRK vs MAINTDRK vs JNJTDRK vs MRKTDRK vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.